18 results
10-K
2023 FY
NMRA
Neumora Therapeutics Inc.
7 Mar 24
Annual report
4:05pm
of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events
424B4
NMRA
Neumora Therapeutics Inc.
18 Sep 23
Prospectus supplement with pricing info
4:12pm
if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well
S-1/A
NMRA
Neumora Therapeutics Inc.
11 Sep 23
IPO registration (amended)
6:07am
more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials
S-1
NMRA
Neumora Therapeutics Inc.
25 Aug 23
IPO registration
5:03pm
dosing regimens, or as the use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts
S-1
EX-10.17
0zik8blhajqkg
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.5
npp979 avh81pdhw9w
25 Aug 23
IPO registration
5:03pm
DRS/A
z0ofe68r 54pm629ukdw
9 Aug 23
Draft registration statement (amended)
12:00am
DRS/A
EX-10.18
wb3k wcfdh7n
9 Aug 23
Draft registration statement (amended)
12:00am
DRS/A
7lpyt4
30 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
urv pbza4e
2 May 23
Draft registration statement (amended)
12:00am
DRS/A
lrr3w7f4ns1lp jh
2 Sep 22
Draft registration statement (amended)
12:00am
DRS/A
rwhd v856i7
10 Jun 22
Draft registration statement (amended)
12:00am
DRS/A
2n42ns1k5f0v ur
2 May 22
Draft registration statement (amended)
12:00am
DRS/A
EX-10.23
m8esq
2 May 22
Draft registration statement (amended)
12:00am
DRS/A
avlm9b7uvf03no
23 Dec 21
Draft registration statement (amended)
12:00am
DRS/A
EX-10.5
df0ske 2skh0
23 Dec 21
Draft registration statement (amended)
12:00am
DRS
uinz9qil g4
8 Nov 21
Draft registration statement
12:00am
- Prev
- 1
- Next